Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Cencora, Inc. COR is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this Zacks Rank #2 (Buy) ...

Those who worked with Billy Jamison say you could not find a better man. And now, coworkers are struggling to move forward.

Artificial Intelligence (AI) was a buzzword around Wall Street for most of 2024. AI has shown immense promise but comes with ...

NRx Pharmaceuticals (NRXP)’ wholly-owned subsidiary Hope Therapeutics signed a Stock Purchase Agreement with Smith & Sauer as the first ...

President Trump said in the "very near future" he will impose tariffs on steel, aluminum, copper, semiconductors, ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...

These stocks have climbed more than 80% and 200% over the past three years. But demand for their products and potential ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a pharmaceutical company with a market capitalization of $22.74 million, has entered into a material definitive agreement and closed a private investment in ...

ANI Pharmaceuticals (ANIP) is a stock many investors are watching right now. ANIP is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Another notable valuation metric for ANIP is ...